# SOIBD Collagenous Colitis Maintenance Study

> **NCT01278082** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 92 (actual)

## Conditions studied

- Induction and Maintaining Remission of Collagenous Colitis

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01278082
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-09
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2016-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278082, "SOIBD Collagenous Colitis Maintenance Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01278082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*